| Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. | |
| | |
MedLine Citation:
|
PMID: 17702596 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Several models have been proposed to explain the mechanisms of endocrine resistance including aberrant growth-signaling pathways, and have led to the rational design of studies combining hormonotherapy with signal transduction inhibitors (STI) in advanced breast cancer. This article reviews the current status of these clinical trials. Preliminary results from the randomized controlled trials are rather disappointing. The mTOR inhibitor temsirolimus and the farnesyl transferase inhibitor tipifarnib combined with letrozole did not show any benefit compared to letrozole alone. As neoadjuvant therapy, gefinitib did not enhance the response rate induced by anastrozole. Interesting results were obtained with exemestane combined to celecoxib but should be further explored with adequate cardiac monitoring. Trastuzumab combined with anastrozole was more effective than anastrozole in terms of response rate and progression-free survival but not survival. Several controlled trials as first- or second-line therapy have started recently and over the next few years we should learn whether this approach will provide significant gains in efficacy. |
| | |
Authors:
|
Joseph Gligorov; David Azria; Moise Namer; David Khayat; Jean-Philippe Spano |
Related Documents
:
|
16519546 - Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvan... 9834826 - Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. 20058066 - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before... 16800976 - Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ov... 19697926 - Ent-kaurane and cembrane diterpenoids from isodon sculponeatus and their cytotoxicity. 7272976 - The abnormal pap smear--what to do next? |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-08-16 |
Journal Detail:
|
Title: Critical reviews in oncology/hematology Volume: 64 ISSN: 1040-8428 ISO Abbreviation: Crit. Rev. Oncol. Hematol. Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-10-05 Completed Date: 2007-12-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8916049 Medline TA: Crit Rev Oncol Hematol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 115-28 Citation Subset: IM |
Affiliation:
|
Medical Oncology Department, CancerEst, Tenon Hospital, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
pharmacology,
therapeutic use* Breast Neoplasms / drug therapy* Clinical Trials as Topic Drug Delivery Systems / methods* Female Hormone Antagonists Humans Signal Transduction / drug effects Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hormone Antagonists |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderl...
Next Document: Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluo...